BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 29641224)

  • 1. Breast cancer: influence of tumour volume estimation method at MRI on prediction of pathological response to neoadjuvant chemotherapy.
    Henderson SA; Muhammad Gowdh N; Purdie CA; Jordan LB; Evans A; Brunton T; Thompson AM; Vinnicombe S
    Br J Radiol; 2018 Jul; 91(1087):20180123. PubMed ID: 29641224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interim heterogeneity changes measured using entropy texture features on T2-weighted MRI at 3.0 T are associated with pathological response to neoadjuvant chemotherapy in primary breast cancer.
    Henderson S; Purdie C; Michie C; Evans A; Lerski R; Johnston M; Vinnicombe S; Thompson AM
    Eur Radiol; 2017 Nov; 27(11):4602-4611. PubMed ID: 28523352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast tumour volume and blood flow measured by MRI after one cycle of epirubicin and cyclophosphamide-based neoadjuvant chemotherapy as predictors of pathological response.
    Stevens W; Farrow IM; Georgiou L; Hanby AM; Perren TJ; Windel LM; Wilson DJ; Sharma N; Dodwell D; Hughes TA; Dall BJ; Buckley DL
    Br J Radiol; 2021 Jul; 94(1123):20201396. PubMed ID: 34106751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of shear wave elastography and Ki-67 index as a novel predictive modality for the pathological response to neoadjuvant chemotherapy in patients with invasive breast cancer.
    Ma Y; Zhang S; Zang L; Li J; Li J; Kang Y; Ren W
    Eur J Cancer; 2016 Dec; 69():86-101. PubMed ID: 27821323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of PET-CT for pathological response in stages II and III breast cancer patients following neoadjuvant chemotherapy with docetaxel.
    García García-Esquinas MA; Arrazola García J; García-Sáenz JA; Furió-Bacete V; Fuentes Ferrer ME; Ortega Candil A; Cabrera Martín MN; Carreras Delgado JL
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):14-21. PubMed ID: 23809513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deep Learning-Based Segmentation of Locally Advanced Breast Cancer on MRI in Relation to Residual Cancer Burden: A Multi-Institutional Cohort Study.
    Janse MHA; Janssen LM; van der Velden BHM; Moman MR; Wolters-van der Ben EJM; Kock MCJM; Viergever MA; van Diest PJ; Gilhuijs KGA
    J Magn Reson Imaging; 2023 Dec; 58(6):1739-1749. PubMed ID: 36928988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Machine Learning With Multiparametric Magnetic Resonance Imaging of the Breast for Early Prediction of Response to Neoadjuvant Chemotherapy and Survival Outcomes in Breast Cancer Patients.
    Tahmassebi A; Wengert GJ; Helbich TH; Bago-Horvath Z; Alaei S; Bartsch R; Dubsky P; Baltzer P; Clauser P; Kapetas P; Morris EA; Meyer-Baese A; Pinker K
    Invest Radiol; 2019 Feb; 54(2):110-117. PubMed ID: 30358693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL.
    Hylton NM; Gatsonis CA; Rosen MA; Lehman CD; Newitt DC; Partridge SC; Bernreuter WK; Pisano ED; Morris EA; Weatherall PT; Polin SM; Newstead GM; Marques HS; Esserman LJ; Schnall MD;
    Radiology; 2016 Apr; 279(1):44-55. PubMed ID: 26624971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
    Symmans WF; Wei C; Gould R; Yu X; Zhang Y; Liu M; Walls A; Bousamra A; Ramineni M; Sinn B; Hunt K; Buchholz TA; Valero V; Buzdar AU; Yang W; Brewster AM; Moulder S; Pusztai L; Hatzis C; Hortobagyi GN
    J Clin Oncol; 2017 Apr; 35(10):1049-1060. PubMed ID: 28135148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing response in breast cancer with dynamic contrast-enhanced magnetic resonance imaging: are signal intensity-time curves adequate?
    Woolf DK; Padhani AR; Taylor NJ; Gogbashian A; Li SP; Beresford MJ; Ah-See ML; Stirling J; Collins DJ; Makris A
    Breast Cancer Res Treat; 2014 Sep; 147(2):335-43. PubMed ID: 25129341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRI Radiomics for Assessment of Molecular Subtype, Pathological Complete Response, and Residual Cancer Burden in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
    Choudhery S; Gomez-Cardona D; Favazza CP; Hoskin TL; Haddad TC; Goetz MP; Boughey JC
    Acad Radiol; 2022 Jan; 29 Suppl 1(Suppl 1):S145-S154. PubMed ID: 33160859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
    Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
    Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer: early prediction of response to neoadjuvant chemotherapy using parametric response maps for MR imaging.
    Cho N; Im SA; Park IA; Lee KH; Li M; Han W; Noh DY; Moon WK
    Radiology; 2014 Aug; 272(2):385-96. PubMed ID: 24738612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy.
    Li SP; Taylor NJ; Makris A; Ah-See ML; Beresford MJ; Stirling JJ; d'Arcy JA; Collins DJ; Padhani AR
    Radiology; 2010 Dec; 257(3):643-52. PubMed ID: 20858850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Longitudinal Variation in Tumor Volume Estimation for MRI-guided Personalization of Breast Cancer Neoadjuvant Treatment.
    Onishi N; Bareng TJ; Gibbs J; Li W; Price ER; Joe BN; Kornak J; Esserman LJ; Newitt DC; Hylton NM; ;
    Radiol Imaging Cancer; 2023 Jul; 5(4):e220126. PubMed ID: 37505107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mammographic breast density: Predictive value for pathological response to neoadjuvant chemotherapy in breast cancer patients.
    Elsamany S; Alzahrani A; Abozeed WN; Rasmy A; Farooq MU; Elbiomy MA; Rawah E; Alsaleh K; Abdel-Aziz NM
    Breast; 2015 Oct; 24(5):576-81. PubMed ID: 26071795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 99mTc-sestamibi using a direct conversion molecular breast imaging system to assess tumor response to neoadjuvant chemotherapy in women with locally advanced breast cancer.
    Mitchell D; Hruska CB; Boughey JC; Wahner-Roedler DL; Jones KN; Tortorelli C; Conners AL; O'Connor MK
    Clin Nucl Med; 2013 Dec; 38(12):949-56. PubMed ID: 24152645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-dimensional ultrasonography of the breast; An adequate replacement for MRI in neoadjuvant chemotherapy tumour response evaluation? - RESPONDER trial.
    van Egdom LSE; Lagendijk M; Heijkoop EHM; Koning AHJ; van Deurzen CHM; Jager A; van Lankeren W; Koppert LB
    Eur J Radiol; 2018 Jul; 104():94-100. PubMed ID: 29857873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-parametric MRI in the early prediction of response to neo-adjuvant chemotherapy in breast cancer: Value of non-modelled parameters.
    O'Flynn EA; Collins D; D'Arcy J; Schmidt M; de Souza NM
    Eur J Radiol; 2016 Apr; 85(4):837-42. PubMed ID: 26971432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Pathologic Response Evaluation Systems After Neoadjuvant Chemotherapy in Breast Cancers: Correlation With Computer-Aided Diagnosis of MRI Features.
    Choi WJ; Kim HH; Cha JH; Shin HJ; Chae EY
    AJR Am J Roentgenol; 2019 Oct; 213(4):944-952. PubMed ID: 31237439
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.